International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 2 Mar-Apr 2023, pp: 1895-1898 www.ijprajournal.com ISSN: 2249-7781

# Case Report on Anaplastic Large Cell Lymphomas (ALCL)

Robin George *[1], M.Rekha[2], Nithya Lakshmi S[2], G.Bhavana[2], T.Bhavitha[2], E Sunil Kumar[1]

[1]*Assistant Professor, Department of Pharmacy Practice, Seven Hills College of Pharmacy, Tirupati, Andhra Pradesh -517561, India.*

[2] *Pharm D Interns, Department of Pharmacy Practice SVIMS-SPMC, Tirupati.*

Submitted: 20-04-2023 Accepted: 30-04-2023

**ABSTRACT:**

Alk-negative anaplastic big mobile lymphoma (ALK(-) ALCL) is an uncommon cd30-high-quality t-mobile lymphoma that offers a primary diagnostic challenge,That comprises ~2% of all person non-hodgkin lymphomas. Based at the presence/absence of the rearrangement and expression of anaplastic lymphoma kinase (ALK), alcl is divided into ALK+ and ALK-, and each differ clinically and prognostically.An extra precise subtype of ALCL is thought to arise after prolonged publicity to breast implants, known as breast implant associated alcl (BIALCL).Here,we present a case of patient by the name V.R.D, 53year old,male got here to OPD with increase length swelling infront of neck in view that 1 month.He had the records of hypertension(HTN)on tab.Torsemide and spirolactone,h/o seizures x 30years on tab.Phenytoin 100mg,retro- viral disease from 2014 on antiretroviral tablets(ARV),meningial TB(2012) finished ATT.On physical examination referred to that 10x7cm lesion over anterior chest wall with more than one smear+ and pallor and cyanosis+.

Laboratory investigations includes chest x-ray,ultrasound. In chest x-ray they identified fibrotic strands in bilateral higher lung region volume loss in left lung,ill described opacities with peri-bronchial cuffing cited in proper lower lung region have been observed. Within the document of ultrasound,hepatomegaly,gross ascites,bilateral mild hydro-ureteronephrosis,bilateral minimum to moderate pleural effussion.Consequently, highlighting this case's rarity, presentation, control, and maximum crucially, control outcome, is the main goal of this paper.

**KEY WORDS:** CD30; DUSP22; JAK/STAT, T-cell lymphoma, anaplastic, ALK-inhibitors; Anaplastic large cell lymphoma, Chemotherapy, Stem cell transplantation.

## I. INTRODUCTION :

Anaplastic large cellular lymphomas (ALCL) are clinically aggressive and pathologically awesome lymphoid neoplasms that originate from a mature post-thymic t-cell. The contemporary global fitness employer (WHO) type of haematologic malignancies acknowledges wonderful subtypes of systemic alcl: anaplastic lymphoma kinase ALK-neg, and ALK-posti.

Alcls are rare among non-hodgkin lymphomas comprising 1-3% typical. There appears to be age and geographic predilection with ALK-POSITIVE ALCL affecting more youthful individuals and being diagnosed greater regularly in north the usa than europe. Both subtypes are quite uncommon in hispanic and asian populations. ALK-positive ALCL sufferers have a better analysis than those with ALK-negative ALCL, and medical functions at presentation.

Signs vary depending at the kind of ALCL(systemic/cutaneous). Both ALK-posi andALK-negALCL regularly cause swollen lymph nodes,in which the most cancers's growing. The most not unusual areas are your neck, underarm and groin. Other signs consist of fever, fatigue, night sweats, unexplained weight loss.

Most people are diagnosed when the cancer is more superior. In superior stages, the cancer may additionally have spread to organs, like your lungs, liver and bone. You could experience signs and symptoms based totally on which elements are affected. As an example, pressure in your chest and a common cough may additionally characterize the presence of the ALCL in your chest.

Healthcare issuer will perform a physical examination to check for signs of ALCL, along with swelling on your lymph nodes. If they suspect ALCL, they'll perform various assessments and tactics.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 2 Mar-Apr 2023, pp: 1895-1898 www.ijprajournal.com ISSN: 2249-7781

Imaging strategies permit your provider to discover the cancer's region. The sort of imaging you'll need depends at the sort of ALCL. A healthcare issuer may carry out a chest X-ray, CT test or MRI to discover tumors. A PET/CT or PET test can show if the cancer has spread throughout your body. A issuer might also perform a breast ultrasound if they think BIA-ALCL.

A healthcare issuer may also carry out diverse blood exams, like a whole blood matter (CBC), to check for signs of ALCL. An atypical amount of blood cells (red- blood cells, white blood cells or platelets) may additionally suggest ALCL. They will additionally test your blood for enzymes and different markers that may be signs of ALCL.

A biopsy is the only way to affirm an ALCL diagnosis. At some stage in a biopsy, your healthcare issuer eliminates a tissue sample and examines the cells beneath a microscope. Reading the cells lets in your provider to determine the kind of ALCL and allows them plan the most relevant treatments.

## II. CASE REPORT:

A 53 years old male patient came to OPD with complaints of increase size swelling infront of neck since 1 month. It is a K/C/O Hypertension (HTN) on Tab.torsemide and spirolactone, H/O Seizures x 30years on Tab.phenytoin 100mg, Retro viral disease from 2014 on antiretroviral drugs(ARV), Meningeal TB(2012) completed ATT.

On examination, noted that 10x7cm lesion over anterior chest wall with multiple smear+ and pallor and cyanosis+. He underwent diagnostic tests like CBC, X-ray chest and Ultrasound were done. In the **Chest x-ray** they identified fibrotic strands in bilateral upper lung zone volume loss in left lung, ill defined opacities with peribronchial cuffing noted in right lower lung zone were found. In the report of**ultrasound**, Hepatomegaly, gross ascites, bilateral mild hydroureteronephrosis, bilateral minimal to moderate pleural effussion.

The laboratory investigations are CBC-Hb-8g/dl,RBC-2.44mm/l,Neutrophils-84C/ml,Lymphocytes-8%,ESR-100mm/hr,PCV-22%. (IMP-Relative neutrophilia.),Serum albumin: 2.8g/dl,Serum alkaline phosphate :175IU/L,SGOT: 37U/L,Serum Total Protein:5.6g/l.

PLAN : PALLATIVE SPECIALIZED RADIATION THERAPY.

The patient was admitted on 8/9/22 in the radiotherapy ward and underwent palliative radiation therapy that is tab ETOPOSIDE PHOSPHATE 40mg/m2 for 14 days and 10 cycles of radiation therapy along with some antibiotics like CEFACTUM [Cefoperazone (1000mg)+sulbactam(500mg) ]1.5GMIVBD,PIPTAZ [Piperacillin(4000mg)+tazobactum(500mg)]4.5GM IVTID for gross ascites and patient was died on 22/9/22.

## III. DISCUSSION :

A 55years old male patient,k/c/o anaplastic large cell lymphoma stage IV(ALK-neg) have underwent 5 cycles of CHOP (Cyclophosphamide,Adriamycin,Vincristin,Prednisolone) at SVIMS from 11/12/2019 to 17/3/2020 and he was defaulted for 5months,again he was suffered from few symptoms of ALCL and started 6 cycles of CHOP at outside hospital. Defaulted for 1 year, now came with increased size swelling infront of neck and planned for 6 cycles of Gemicitabin and Oxaliplatin,underwent 2 cycles on 11/3/2022 and 1/5/2022 and regimen changed to Tab.ETOPOSIDE been clinicaly programmed daily along with specialized radiation therapy.

## IV. STAGING SYSTEM

The standard staging system used for ALCL is the same as that proposed for Hodgkin's complaint at the Ann Arbor Conference in 1971( 6). This system is presently used for all non-Hodgkin's lymphomas, indeed if other staging systems are used in some extra-nodal lymphomaswith particular natural behaviours. The Ann Arbor staging system reflects both the number of spots of involvement and the presence of complaint above or below the diaphragm. Cases are divided into two sub-sets according to the presence( A) or absence( B) of systemic symptoms. Fever of no apparent cause, night sweats and weight loss of further than 10 of body weight are considered systemic symptoms. The presence of big mass, such as lesion od 10cm or more in the longest diameter is gestured as " X ", while the extranodal involvement should be linked by a symbol( O bone, L lung, D skin,etc.).

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 2 Mar-Apr 2023, pp: 1895-1898 www.ijprajournal.com ISSN: 2249-7781

Table 2.Ann Arbor staging system.

| Stage | Clinical Presentation |
|---|---|
| Stage I | Involvement of a single lymph node region or single lymphoid structure, similar as spleen, thymus or Waldeyer ring (I), or a single extranodal point( IE). |
| Stage II | Involvement of two or further lymph node regions or lymphoid structures on the same side of the diaphragm( II) or localized involvement of an extralymphatic point( IIE). The number of anatomical regions involved should be represented by a subscript(e.g., II3). Mediastinal bumps are a single lymph node region. |
| Stage III | Involvement of lymph nodes regions or lymphoid structures on both sides of the diaphragm (III), or localized involvement of an extralymphatic site (IIIE), or spleen (IIIs) or both (IIIEs). Moreover, stage $III_1$ – characterized by splenic, hilar, coeliac or portal node involvement – can be differentiated from stage $III_2$ which presents para-aortic, iliac and/or mesenteric node involvement. |
| Stage IV | Diffuse or circulated involvement of one or further extralymphatic organs with or without associated lymph node involvement. Localized involvement of liver or bone marrow is also considered stage IV. |
| Extra nodal disease | Extra nodal categorization in stages I – III includes a single extra lymphatic involvement by limited direct extension from an conterminous nodal point. Extra nodal involvement should be linked by a symbol( M gist, L lung, D skin, H liver, P pleura, O bone). |
| Systemic symptoms | Fever> 38 °C of no apparent cause for 3 successive days, night sweats and unexplained weight loss> 10% of body weight. Cases are divided according to the presence( B) or not( A) of these symptoms. |
| Bulky disease | Palpable masses and abdominal masses ( CTcheckup or MRI) are defined as " big " when its largest dimension is ≥ 10 cm. Mediastinal mass is defined as " big " on a posteroanterior chest radiograph, when the maximum range is ≥ one- third of the internal transverse diameter of abdomen at the position of T5 – T6 vertebrae. |

**Treatment of primary ALCL-ALK−**

The optimal remedy for ALCL- ALK − is controversial due to the peculiarity of this complaint, the variety of clinical symptoms, and the lack of randomized trials concentrated on this carcinoma. ALCL- ALK − is generally analysed together with other T- cell lymphomas.

Chemotherapy for supplemental T- cell lymphomas has been extracted from experience in aggressive B- cell carcinoma. CHOP( cyclophosphamide, doxorubicin, vincristine, prednisone) is the most generally used option to treat systemic ALCL. In a retrospective series, ALCL- ALK − cases treated with 2nd- and 3rd-generation chemotherapy regimens showed an ORR and disease remission rates( CRR) of 84%and 56%, independently, with a 10-years complaint-free survival( DFS) of 28% suggesting that more dose regimen didn't impact outcome(7). Encouraging results have been reported with ACVBP chemotherapy(doxorubicin, cyclophosphamide, vindesine, bleomycin,

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 2 Mar-Apr 2023, pp: 1895-1898 www.ijprajournal.com ISSN: 2249-7781

prednisone) followed by a consolidation treatment with high-dose methotrexate, ifosfamide, etoposide, asparaginase, and cytosine- arabinoside or m- BACOD( methotrexate, bleomycin, Adriamycin, cyclophosphamide, vincristine, dexamethasone), VIMMM(VM26,ifosfamide, mitoxantrone, methyl- monkeyshine, methotrexate)/ ACVBP, and CHOP( 8). Cases with T- cell ALCL had a CR rate of 69% and a 5- years OS of 63, still, cases weren't stratified by ALK expression; 75 were< 60years of age and 40% had stage I or II complaint. The NHL- B1 trial added etoposide to CHOP and reduced the treatment interval from 21 to 14 days in youthful pts with aggressive NHL and good prognostic labels. In a multivariate analysis, CHOP- 14 was associated with bettered EFS and OS compared to CHOP- 21 in aggressive lymphomas,butthere were limited number of cases with T- cell carcinoma( 9). More lately the German high grade aggressive NHL study collected a retrospective series of 320 cases with supplemental T- cell carcinoma from 7 phase II and III trials, including NHL- B1 and NHL- B2(10). In total, there were 191 cases with ALCL including 113 cases of ALCL- ALK − treated with CHOP( CHOP- 14, CHOP- 21), CHOEP( CHOP- 14/21 plus etoposide) or boosted CHOEP( High-CHOEP14/ 21 orMega-CHOEP). The 3- time EFS and OS were 46 and 62, independently, in cases with ALCL- ALK −. In youngish cases with a normal LDH an bettered EFS, but not OS, was observed. still, there was only a trend to bettered EFS( p = 0.057) when cases with ALK+ ALCL were barred. The analysis wasn't simply confined to cases with ALK- ALCL.

## REFERENCES

1. Armitage J, Vose J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J ClinOncol 26(25):4124–4130. https://doi.org/10.1200/JCO.2008.16.4558
2. Adams SV, Newcomb PA, Shustov AR (2016) Racial patterns of peripheral T-cell lymphoma incidence and survival in the united states. J ClinOncol
3. Savage KJ, Harris NL, Vose JM et al (2008) ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood 111(12):5496–5504
4. Medeiros LJ, Elenitoba-Johnson KS (2007) Anaplastic large cell lymphoma. Am J ClinPathol 127(5):707–722
5. Schmitz N, Trumper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the german high-grade non-hodgkin lymphoma study group. Blood 116(18):3418–3425
6. P.P. Carbone, H.S. Kaplan, K. MusshoffReport of the Committee on Hodgkin's disease staging classification,Cancer Research, 31 (November (11)) (1971), pp. 1860-1861
7. P.L. Zinzani, M. Bendandi, M. Martelli,Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients,Journal of Clinical Oncology, 14 (March (3)) (1996), pp. 955-962
8. R. Suzuki, Y. Kagami, K. Takeuchi, et al.,Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype,Blood, 96 (November (9)) (2000), pp. 2993-3000
9. M. Pfreundschuh, L. Trümper, M. Kloess, et al.,Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL,Blood, 104 (August (3)) (2004), pp. 634-641
10. N. Schmitz, L. Trümper, M. Ziepert, et al.,Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group,Blood, 116 (November (18)) (2010), pp. 3418-34